Active, not recruitingPhase 3NCT04639180
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Studying Leukoencephalopathy with calcifications and cysts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Intervention
- Camrelizumab(drug)
- Enrollment
- 687 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (6)
- The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
- Guangxi Medical University Affiliated Tumor Hospital, Nanjin, Guangzhou, China
- Guizhou Cancer Hospital, Guiyang, Guizhou, China
- Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
- Zhongshan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
- Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04639180 on ClinicalTrials.govOther trials for Leukoencephalopathy with calcifications and cysts
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT0685282068Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)Melissa Lumish
- RECRUITINGNANCT04996914Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular CarcinomaRWTH Aachen University
- RECRUITINGPHASE2NCT07219459Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureCatalYm GmbH
- ACTIVE NOT RECRUITINGPHASE2NCT07380633Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative TrialSun Yat-sen University
- RECRUITINGNCT07432347Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics ApproachesNiguarda Hospital
- RECRUITINGNCT07436845Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and ImmunotherapyNanfang Hospital, Southern Medical University
- RECRUITINGPHASE2NCT07274774SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular CarcinomaShandong Cancer Hospital and Institute
- RECRUITINGPHASE1NCT07275073JMT106 Injection in the Treatment of Advanced Solid TumorsShanghai JMT-Bio Inc.
See all trials for Leukoencephalopathy with calcifications and cysts →